News Focus
News Focus
icon url

DewDiligence

09/27/17 2:29 PM

#213900 RE: DewDiligence #213839

(ADXS)—ADRO is yet another neoantigen competitor:

https://globenewswire.com/news-release/2017/09/27/1133689/0/en/Aduro-Biotech-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-Personalized-Immunotherapy-pLADD-Based-on-Proprietary-Neoantigen-Technology.html

The single indication in ADRO’s phase-1 trial is second-line colorectal cancer.

ADXS NEO’s phase-1, which has not yet enrolled any patients (#msg-134670005), will (purportedly) be tested in NSCLC, H&N cancer, and CRC.